Regenxbio Inc (NASDAQ:RGNX) gapped down before the market opened on Monday . The stock had previously closed at $39.65, but opened at $35.20. Regenxbio shares last traded at $27.85, with a volume of 2384100 shares traded.
Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. ValuEngine downgraded shares of Regenxbio from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Chardan Capital increased their price objective on shares of Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Bank of America reissued a “buy” rating and set a $38.00 price objective (up previously from $33.00) on shares of Regenxbio in a research report on Monday, October 9th. Finally, Barclays assumed coverage on shares of Regenxbio in a research report on Wednesday, November 22nd. They set an “overweight” rating and a $38.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Regenxbio presently has a consensus rating of “Buy” and an average target price of $42.43.
The company has a market cap of $826.91 and a price-to-earnings ratio of -9.72.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. The business had revenue of $1.34 million during the quarter. equities research analysts expect that Regenxbio Inc will post -2.71 EPS for the current year.
In related news, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $27.71, for a total transaction of $277,100.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Curran Simpson sold 2,000 shares of the stock in a transaction on Monday, November 27th. The stock was sold at an average price of $29.31, for a total transaction of $58,620.00. Following the transaction, the senior vice president now owns 41,500 shares of the company’s stock, valued at approximately $1,216,365. The disclosure for this sale can be found here. Insiders have sold 94,000 shares of company stock valued at $2,947,446 in the last 90 days. 17.00% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. State Street Corp boosted its holdings in Regenxbio by 178.1% during the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock worth $17,399,000 after purchasing an additional 564,129 shares during the last quarter. GMT Capital Corp boosted its holdings in Regenxbio by 1,086.2% during the second quarter. GMT Capital Corp now owns 609,700 shares of the biotechnology company’s stock worth $12,346,000 after purchasing an additional 558,300 shares during the last quarter. Redmile Group LLC boosted its holdings in Regenxbio by 35.4% during the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after purchasing an additional 449,540 shares during the last quarter. Citadel Advisors LLC boosted its holdings in Regenxbio by 65.4% during the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after purchasing an additional 366,289 shares during the last quarter. Finally, RTW Investments LP lifted its stake in Regenxbio by 20.9% in the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock valued at $50,710,000 after acquiring an additional 266,235 shares during the last quarter. Institutional investors and hedge funds own 68.73% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Regenxbio (RGNX) Shares Gap Down to $35.20” was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/10/regenxbio-rgnx-shares-gap-down-to-35-20.html.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.